Lactoferricin B Combined with Antibiotics Exhibits Leukemic Selectivity and Antimicrobial Activity

The fusion of penetrating peptides (PPs), e.g., cell penetration peptides (CPPs) or antimicrobial peptides (AMPs), together with antimicrobial agents is an expanding research field. Specific AMPs, such as lactoferricin B (LfcinB), have demonstrated strong antibacterial, antifungal, and antiparasitic activity, as well as valuable anticancer activity, proving beneficial in the development of anticancer conjugates. The resulting conjugates offer potential dual functionality, acting as both an anticancer and an antimicrobial agent. This is especially necessary in cancer treatment, where microbial infections pose a critical risk. Leukemic cells frequently exhibit altered outer lipid membranes compared to healthy cells, making them more sensitive to compounds that interfere with their membrane. In this study, we revisited and reanalyzed our earlier research on LfcinB and its conjugates. Furthermore, we carried out new experiments with a specific focus on cell proliferation, changes in membrane asymmetric phosphatidylserine location, intracellular reactive oxygen species (ROS) generation, mitochondrial functions, and in vitro bacterial topoisomerase inhibition.


Introduction
The possibility of combining different types of chemical compounds has given rise to the development of new molecules with improved pharmacological characteristics.Among these are peptides and antimicrobial conjugates, which offer expanded molecular targets, reduced toxicity, and the ability to overcome drug resistance when compared to their original substances [1][2][3][4][5][6][7][8].CPPs and AMPs are two types of PPs that demonstrate not only antimicrobial properties but also anticancer potential [2,4,[9][10][11][12][13][14][15][16][17].Table 1 showcases the functional classification of PPs, and The impact of PPs on biological systems can be altered, improved, and prolonged by making structural modifications to the peptide itself or by linking it to other compounds.As previously demonstrated, CPPs such as TP10 and its fluoroquinolone conjugates show antibacterial and antileukemic effects, minimal generation of ROS, and a slight impact on mitochondrial functions [8,16].Crucially, leukemic cells frequently display disturbances in the outer lipid membrane, making them highly sensitive to compounds that interfere with membrane integrity [18][19][20][21][22][23][24][25].These lipid disturbances have been identified as a cellular target for hematological malignancies [26][27][28][29][30]. Microbial infections are a significant contributing factor to the morbidity and mortality of acute leukemia (AL) patients, with a median incidence reaching around 27% [31].This issue is particularly pronounced in immune-deficient patients, such as children with AL, and older patients with various types of leukemia [32][33][34][35][36].For this reason, treatment requires the use of immunosuppressive drugs, which in turn increases the risk of microbial infections.The standard antimicrobials employed in this context are ciprofloxacin (CIP) and levofloxacin (LVX) [37][38][39].It is well established that the ability of CIP and LVX to exhibit antibacterial activity relies on the inhibition of topoisomerase (a mechanism also applied in cancer treatment) [40][41][42].Unfortunately, both CIP and LVX demonstrate some unwanted effects, including toxicity induced by ROS [43][44][45][46].
In this latest update, delving deeper into the previously discussed results regarding the biological effects of LfcinB and its combination with an antibiotic [48], we conducted additional MTT tests specifically for compound 4 (LfcinB covalently linked to fluconazole (FLC)), focusing on the HL60 and HEK293 cell lines.Furthermore, we calculated the Bacteriostatic Selectivity Index (B SI ), Fungistatic Selectivity Index (F SI ), and Malignancy Selectivity Index (M SI ).To assess the basal molecular impact of LfcinB and selected conjugates on bacteria, we examined S. aureus alterations in the membrane asymmetric distribution of phosphatidylserine.Additionally, we conducted in vitro bacterial topoisomerase inhibition assays.Furthermore, we expanded our research on potential toxicity by examining intracellular ROS generation in HL60 and HEK293 and assessing their influence on mitochondrial functions.
Highlighting their leukemic selectivity and antimicrobial activity, along with a minimal impact on ROS generation and mitochondrial function, we have identified an interesting compound, designated as number 3 (disulfide bridge between LfcinB and CIP).This conjugate demonstrates all these properties at an IC 50 in micromolar concentrations and an EC 50 (effective concentration; IC normalized to cell number [63]) in the nanomolar range.It is worth noting that conjugate 3 serves as an example of a disulfide connection between parenteral drugs, representing a promising target for enzymatic reduction.

Inhibition of Cancer Cell Proliferation and EC 50 of Lfcin and Its Conjugates
To enhance the previously published dataset on the inhibition of cancer cell growth by LfcinB and its conjugates [48], we conducted additional experiments for conjugate 4 on HL60 and HEK293.The antiproliferative effects of LfcinB and its conjugate 4 were evaluated using the MTT assay, and the calculated IC 50 values are detailed in Supplementary Table S1.However, the cellular response to compound 4 for HL60 was approximately 65 µM.It is noteworthy that the IC 50 of the leukemic cells was still approximately 2.5 times lower than that observed in healthy HEK293 cells.
When it comes to calculating and comparing EC 50 values for LfcinB and all its conjugates (Figure 1a) on HL60, BT20, A549, and HEK293 cell lines, conjugates 1 (covalently bonded LfcinB and LVX) and 3 proved to be the most active against cancer cells, with EC 50 values ranging from 3 to 69 nM (Supplementary Table S2).By contrast, conjugate 4 exhibited an EC 50 of 108 nM in healthy HEK293 cells.Notably, the EC 50 values for the FLC conjugate were approximately twice as high as those for conjugates containing CIP and LVX on all tested cancer cell lines (Supplementary Table S2).The most significant growth inhibition was observed for conjugate 3 on HL60, with an EC 50 of 3 nM, while the highest values were recorded for LfcinB (499 nM) and conjugate 3 (409 nM) in HEK293.The most sensitive cell line to the action of LfcinB and all tested conjugates was HL60, with EC 50 values ranging from 3 to 13 nM; the least sensitive turned out to be HEK293, with EC 50 values ranging from 108 to 499 nM (Supplementary Table S2).
approximately 65 µM.It is noteworthy that the IC50 of the leukemic cells was still approximately 2.5 times lower than that observed in healthy HEK293 cells.
When it comes to calculating and comparing EC50 values for LfcinB and all its conjugates (Figure 1a) on HL60, BT20, A549, and HEK293 cell lines, conjugates 1 (covalently bonded LfcinB and LVX) and 3 proved to be the most active against cancer cells, with EC50 values ranging from 3 to 69 nM (Supplementary Table S2).By contrast, conjugate 4 exhibited an EC50 of 108 nM in healthy HEK293 cells.Notably, the EC50 values for the FLC conjugate were approximately twice as high as those for conjugates containing CIP and LVX on all tested cancer cell lines (Supplementary Table S2).The most significant growth inhibition was observed for conjugate 3 on HL60, with an EC50 of 3 nM, while the highest values were recorded for LfcinB (499 nM) and conjugate 3 (409 nM) in HEK293.The most sensitive cell line to the action of LfcinB and all tested conjugates was HL60, with EC50 values ranging from 3 to 13 nM; the least sensitive turned out to be HEK293, with EC50 values ranging from 108 to 499 nM (Supplementary Table S2).S2.S2.

The Biological Selectivity of LfcinB and Its Conjugates 2.2.1. Bacteriostatic Selectivity
B SI values were analyzed for the following bacteria strains: S. epidermidis, B. subtilis, S. aureus, E. coli, P. aeruginosa, and B. cereus, as well as the following cell cultures: leukemia (HL60), breast cancer (BT20), non-small-cell lung cancer (A549), and non-cancerous embryonic kidney cells (HEK293), represented by MIC/IC 50 (Supplementary Table S2) and B SI indexing as illustrated in Figure 1b.
LfcinB and conjugate 3 demonstrated the most favorable B SI values across all tested cell lines and bacterial strains (Figure 1b).S. epidermidis exhibited highly favorable B SI values of >5 and <472, while B. cereus showed the least favorable B SI values of <0.7 and <16 (Figure 1b and Supplementary Table S2).For HEK293, all B SI calculations for LfcinB and its conjugates indicated high favorability (>2) against all tested strains.Conjugate 3 achieved the best score against S. epidermidis with a B SI > 471, and LfcinB showed a B SI > 179.
The least favorable index was noted for the HL60 cell line, where, apart from the values for S. epidermidis, with B SI values ranging from >6 to <13, the index varied from unfavorable (B SI > 0.7), as seen in the case of conjugate 3 on B. cereus, to very good (B SI > 13 and <14), as observed with conjugate 2 (alternative disulfide bridge connection between peptide and CIP) on S. epidermidis.Mostly the index was not more than around 3, mainly remaining approximately around 0.7 (Figure 1b and Supplementary Table S2).This outcome shows that, in HL60, the bacteriostatic effect is less efficient than the cytostatic effect obtained on leukemic cells.For the BT20 cell line, the B SI results were similar to those for HL60, with the cancer cytostatic effect, especially for conjugates 1 and 2, surpassing the bacteriostatic one (Figure 1b).Notably, the difference in the action of conjugates 2 and particularly 3 (connected by disulfide bonds) between HL60 and BT20 for E. coli, P. aeruginosa, and B. cereus suggests that such a difference in combination might be associated with a more selective cytostatic effect against leukemia (Figure 1b).
Conjugate 4 (containing FLC) and LfcinB exhibited the most desirable F SI values across all tested cell lines and bacterial strains (Figure 1b).C. krusei showed favorable F SI values of >7 and <34, while the other three strains demonstrated lower F SI values of <0.7 and <18 (Figure 1b and Supplementary Table S2).Similarly, for HEK293, all F SI calculations for LfcinB and its conjugates indicated favorability (>2) against all tested strains.Conjugate 3 exhibited a favorable F SI ranging from >15 to <31 for all strains.
The least favorable index was noted for HL60 (Figure 1b).The index was mostly unfavorable (F SI > 0.7) or moderate (<0.7 and >1), and very good in the case of C. krusei for compounds 1 and 4, with F SI values of 2.9 and 2.4, respectively.As for B SI , the fungistatic effect was lower than the antiproliferative effect on leukemic culture.
The F SI results for BT20 resembled those for HL60.The main differences observed across all strains were a more favorable F SI for BT20 with LfcinB and conjugate 3, while it was less favorable for conjugate 2. Therefore, as in the case of B SI , the differences in F SI may suggest a more selective cytostatic effect against leukemic cells (Figure 1b).

Malignancy Selectivity
To evaluate their effect on leukemia, cancer, and non-cancer cells, the Malignancy Selectivity Index was calculated as M SI = EC 50 (non-cancerous)/EC 50 (leukemic or cancerous) or EC 50 (leukemic or cancerous)/EC 50 (leukemic or cancerous).These data are presented in Supplementary Table S3 and visualized in Figure 1c.Most compounds displayed higher M SI values for cancerous, especially leukemic, cells than for healthy cells (Figure 1c, Supplementary Table S3).
M SI values for all compounds reached their peak for HL60, ranging between >3 and the highest score of <136, which was obtained for compound 3 on HEK293 (refer to Supplementary Table S3).LfcinB also displayed promising M SI parameters for HL60, attaining values of between >8 and <52.Furthermore, disulfide bridge conjugates 2 and 3 exhibited higher M SI values in HL60 than was the case for their counterpart 1 and without the bridge connection (see Figure 1c).HL60 was the only cell line that exhibited favorable M SI values across all compounds when compared to the two other cancer cell lines and the non-cancerous HEK293 cells.Notably, all the compounds demonstrated selectivity towards healthy cells, indicated by negative M SI values (Figure 1c).

LfcinB and Its Conjugates Eliminating Bacteria 2.3.1. Switch the Asymmetry in Membrane Phospholipids
Our study incorporates insights from Dwyer's research, emphasizing that bacteria can display essential characteristics of eukaryotic cell death [64].In the dot plots shown in Figure 2a (7AAD vs. Annexin V), there is a notable reduction in the number of events over 6 h in samples treated with compounds compared to the untreated control.Specifically, when compared to LfcinB, the impact of conjugate 3 (at MIC concentrations) is more pronounced, as reflected in a lower number of events from the first hour to 6 h.At this point in time, we observed essential disturbances in the asymmetric distribution of phosphatidylserine in the membrane (as indicated by the Annexin V level), leading to a loss of integrity (evidenced by 7AAD accumulation) and subsequent cell death.Consequently, the bacteriostatic effect induced by the compound also manifests as bactericidal (Figures 1b and 2a).

DNA Gyrase and Topoisomerase IV Inhibition
Disruptions in the membrane, triggered by the treatment with compounds, result in a loss of cell integrity, enhancing the entry of these compounds into the cell.Our study indicates that topoisomerase IV serves as the primary target for quinolones and their conjugates.We evaluated seven compounds for their inhibitory effects on S. aureus topoisomerases using three assays: gyrase activity, relaxation, and topoisomerase IV activity (Figure 2b).The LfcinB peptide alone exerted the most significant impact on topoisomerase IV relaxation activity, while compound *5 (chimera CH9 of HNP-1; for more details please refer to [43]) demonstrated the highest inhibitory effect among tested compounds (Figure 2b).Notably, LfcinB, when conjugated with CIP, exhibited a relatively high inhibitory effect on all enzyme activities, compared to its connection to LVX (Figure 2b).

LfcinB and Its Conjugates Exhibit Low Toxicity in Human Cell Lines
To verify whether the observed leukemic-selective cytostatic effect is potentially toxic, we expanded our previous studies [48] to include the evaluation of intracellular ROS generation by compound 4 (Figure 2c).Furthermore, we investigated the impact of the selected conjugate on mitochondrial functions (Figure 2d).The ROS-generating activity of conjugate 4 with FLC was evaluated in the HL60 and HEK293 cell lines (Figure 2c).We employed the fluorescent CM-H2DCFDA probe for ROS detection, with H 2 O 2 used as a positive control due to its known role as an ROS inducer.Incubation with compound 4 (at 2-fold IC 90 ) resulted in negligible levels of cellular ROS (Figure 2c).Importantly, these findings align with the data reported for conjugates 1-3, as detailed in our earlier publication [48].The obtained evidence strongly suggests that the cytostatic effect is ROS-independent (Figure 2c).To investigate further, we examined whether the compounds could cause mitochondrial dysfunction.To confirm this, we assessed mitochondrial potential through flow cytometry using HL60 cells stained with DIOC6(3) and treated with compound 3 (Figure 2d).Our analysis showed that the tested conjugate had a minimal impact on mitochondrial potential, suggesting a low risk of toxicity in this context.

Antimicrobial Effect
AMPs are small, positively charged molecules with amphipathic structures.They are found widely in animal tissues and serve as a crucial first line of defense against infections.AMPs exhibit a broad spectrum of activity, mainly targeting bacteria, fungi, and viruses [65], and this phenome extends to LfcinB and its conjugates as well (Figure 1a,b).The primary mode of action involves the direct disruption of microbial cell membranes and selective binding to negatively charged phospholipid head groups on bacterial membranes [66].According to our findings, this type of effect occurs not only for LfcinB (Figure 2a).Importantly, AMPs are not attracted to neutral host cell membranes [67].This effect might have influenced the low activity of all tested compounds against non-cancerous HEK293 cells and their significantly higher activity against cancerous and leukemic cells (Figure 1c).
In addition to membrane disruption, AMPs can impact microbial cells through various mechanisms, including interactions with intracellular targets such as nucleic acids or proteins, as well as the disruption of cellular processes.Fluoroquinolones exert their antimicrobial effect by inhibiting two essential enzymes involved in bacterial DNA synthesis: DNA gyrase and topoisomerase IV [68].DNA gyrase introduces negative supercoils in bacterial DNA, facilitating the separation of the daughter chromosomes necessary for replication initiation.Topoisomerase IV is responsible for the decatenation process, sep-arating daughter chromosomes at the end of replication [69,70].Fluoroquinolones form complexes with either DNA gyrase or topoisomerase IV bound to bacterial DNA, causing conformational changes that deactivate these enzymes.This interference impedes the progression of the replication fork and bacterial DNA synthesis, ultimately leading to rapid bacterial cell death [68].Figure 2b illustrates the inhibition of the DNA-gyrase in Gram-negative and DNA-topoisomerase IV in Gram-positive bacteria in an in vitro assay induced by fluoroquinolones.
The impact of lactoferrin on gut microbiota and toll-like receptors (TLRs) in mice undergoing microbiota imbalance due to antibiotic treatment was also published [71].The effects of antibiotic therapy on gut microbiota were explored, emphasizing the potential for dysbiosis, a disruption in microbial balance.The primary focus was on understanding how the composition of gut microbiota and TLR expression was regulated by lactoferrin.Concluding insights underscored the significance of the findings, emphasizing the intricate interplay between lactoferrin, gut microbiota, and the immune system.

Antileukemic Selectivity and Low Potential Toxicity
Leukemic cells, sensitive to compounds disrupting the outer lipid membrane, represent a target for hematological malignancies [72].As we previously demonstrated with CPP, TP10, and its conjugates with CIP and LVX, these compounds exhibit selective and low toxicity toward leukemic cells [16].Consequently, certain AMPs may also be active against these cell types.Our research revealed that LfcinB and its conjugates exhibit selectivity towards leukemic cells, antimicrobial activity, and a minimal impact on ROS generation and mitochondrial function (Figures 1 and 2c,d).These AMPs, when combined with antimicrobial agents, demonstrate potential for effectively targeting leukemic cells and managing infections during HCT.
In terms of structure, the distinction between conjugates and a mixture of LfcinB with an antibiotic (CIP or LVX or FLC) is characterized by the presence of a covalent or disulfide bridge bond linking LfcinB to the antibacterial or antifungal agent.In the case of conjugates, delivery inside cells is coordinated and potentially improved, as the cell membrane can be made permeable by the presence of conjugate oligomers.These conjugates, located within cellular components, serve as effective targets for enzymatic reduction, leading to the subsequent release of individual components within the cell, binding to certain targets and causing damage to cellular pathways.Various mechanisms may contribute to making conjugates more advantageous in vivo, aspects that prove challenging to discern within an in vitro environment.These factors encompass co-targeting specific tissues, heightened metabolic stability, decreased toxicity prior to linker cleavage, and a diminished likelihood of developing resistance during prolonged treatment.It is important to note that these considerations remain speculative until promising candidate drugs are selected for animal studies.
Analyzing data from lactoferrin studies in both rats [73] and humans [74][75][76][77], as well as talactoferrin [78] studies in humans, indicates that LfcinB can be classified as biologically safe.There were no reported hematological, hepatic, or renal toxicities during therapy.Notably, 88% of patients observed a reduction in their tumor growth rate.The research also revealed a positive correlation with the immune system through binding mechanisms [79,80].LfcinB demonstrates potential immunomodulatory functions, influencing the host's immune response.By enhancing the immune system's ability to recognize and eliminate pathogens, LfcinB contributes to overall biological safety by fortifying the body's natural defense mechanisms.The peptide's stability and resistance to enzymatic degradation further contribute to its biological safety.These characteristics ensure the sustained availability of LfcinB at the site of action, optimizing its therapeutic efficacy while minimizing potential systemic side effects.

Determination of Drug Cytotoxicity
As mentioned in [61], we followed detailed procedures, including the composition of media and growth conditions, for the application of conjugate 4 on both HL60 and HEK293 in the MTT drug sensitivity assay.The initial cellular density for cultures seeded in a 96-well plate was 5000 cells/well for HL60 and 1500 cells/well for HEK293.

Switch of S. aureus Asymmetric Phosphatidylserine Location
Bacterial cultures with an OD200, as utilized in bacteriostatic experiments (Ptaszy ńska et al., 2019 [16,48]), were plated on Petri dishes.Compounds were added at the MIC concentration to the test sample, while no compound was added to the negative control.After an appropriate incubation period (45 min, 2.45 min, and 5.45 min), samples were collected and promptly washed with PBS.The pellet was then suspended in 100 µL of annexin binding buffer (BioSource International, Camarillo, CA, USA), which included 0.25 µL of 7-AAD (7-aminoactinomycin D, 1 mg/mL, Sigma) and 1 µL of Annexin-FITC (Thermo Fisher, Waltham, MA, USA).Following the addition of 400 µL of annexin binding buffer, the samples were left in the dark for 15 min.Subsequently, the samples were placed on ice and immediately read by the Guava EasyCyte (Merck-Millipore, Burlington, MA, USA).Flow results were analyzed with the free online software https://floreada.io/(accessed on 30 November 2023; the last update was carried out in June 2023).

Inhibition of S. aureus Gyrase and Topoisomerase IV Activities
Inhibitory concentrations for three gyrase and topoisomerase IV activities were assessed: gyrase supercoiling, TOPO IV relaxation, and TOPO IV decatenation.For this, commercially available kits were used (S.aureus gyrase supercoiling assay kit, S. aureus topoisomerase IV relaxation assay kit, and topoisomerase IV decatenation kit all purchased from Inspiralis (Norwich, UK)).The procedure was carried out according to the manufacturer's instructions.The substrates for the reactions were 500 ng of the relaxed pBR322 plasmid, 500 ng of supercoiled pBR322, or 200 ng of kinetoplast DNA (kDNA) from Crithidia fasciculate, respectively.The studied compounds were dissolved and diluted in dd H 2 O at the experimentally selected concentrations (gyrase: 2000-250 µM for CIP, 1000-50 µM-LVX, 500-50 µM conjugates; topoisomerase: 500-5 µM CIP/LVX, 250-10 µM-conjugates).Appropriate controls were included (with or without the enzyme or without the addition of the tested compound).After the addition of the indicated amount of the enzyme, the reaction proceeded at 37 • C for 30 min.Loading buffer was used for reaction termination.The studied compounds were extracted from the reaction mixtures with 30 µL of a chloroform/isoamyl alcohol solution (24:1; v/v).After centrifugation (3 min, 20,000× g), the upper aqueous phase was loaded onto 1% agarose gels and run at 90 V for 4 h in TBE buffer (90 mM Tris-base, 70 mM boric acid, 1 mM EDTA, pH 8).Gels were stained with 1 µg/mL ethidium bromide (Sigma, Burbank, CA, USA) for 15 min to visualize the DNA, and unbound ethidium bromide was removed by washing the gel in dd H 2 O for 15 min.

Intracellular ROS Generation
Cell lines were cultured as mentioned above and seeded in Petri dishes (Falcon, Cary, NC, USA) in the amount of 25 × 10 3 per Φ35 dish.HEK293 cells were allowed to attach overnight.ROS generation potential was tested for selected compounds after 0.25, 0.5, 1, 3, 6, and 24 h of incubation.The CM-H2DCFDA molecular probe (Thermo Fisher Scientific, Waltham, MA, USA) at a final concentration of 1 µM was added 15 min before the analysis.After staining, HEK293 cells were trypsinized, harvested, and suspended in fresh media.The 7AAD (Cat.A9400, Sigma Aldrich) was added just before analysis.Analyses were carried out with a Guava EasyCyte flow cytometer (Merck-Millipore, USA).Flow cytometry data were processed with Flowing Software 2.5.1 (Turku Bioscience, Turku, Finland).

Conclusions
Combining PPs with antimicrobial agents shows potential for effectively targeting leukemic cells and addressing infections during HCT.So far, there have not been similar applications of such compounds in leukemia treatment.The conventional approach, as seen in AML, still relies on the use of non-specific therapies while simultaneously aiming for autologous transplantation.In the processes of conditioning, myeloablation, and immunosuppression, cytostatics such as cyclophosphamide [81][82][83][84][85][86][87] and preventive antibiotics such as CIP or LVX are employed.Cyclophosphamide exhibits low selectivity and is combined with the administration of antibiotics, resulting in a less intense synergistic effect and less tissue-specific availability compared to LfcinB.We believe that our research will involve the generation of new structures, which can successfully be applied in the development of therapy for treating leukemia and infections.The optimization of these structures can occur through the careful selection of the PP type and the attached bacterial or anticancer compound.

Supplementary Materials:
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules29030678/s1.Supplementary Table S1.Cellular effect of compound no.4; Supplementary Table S2.Effective concentration values.;Supplementary Table S3.Antimicrobial Selectivity Index of LfcinB and selected conjugates in relation to IC 50 values for HL60, BT20, A549, and HEK293; Supplementary Table S4.Normalized to EC 50 Malignancy Selectivity Index; Supplementary Table S5.Physicochemical properties of peptide conjugates and its components; Supplementary Figure S1.MS analysis of peptide and peptide conjugates and their constituents.

s
2024, 29, x FOR PEER REVIEW 7 of 15

Figure 2 .
Figure 2. Effectiveness of LfcinB and its bioconjugates in biological systems.(a) The bactericidal activity of LfcinB and its bioconjugate 3. Two-parameter dot plots showcase the shift in the asymmetric localization of phosphatidylserine in the external membrane induced by the compound in S. aureus (Annexin V-positive events derived from the right top and bottom squares of the discriminator).The outcomes of the flow cytometry were analyzed with the free online software Floreada.io(https://floreada.io/(accessed on 30 November 2023; the last update was carried out in June 2023)).Representative data are based on three independent repetitions.(b) The compound hinders the supercoiling activity of gyrase.Controls include KBZ, representing the sample without the compound, and KBE, representing the sample without the enzyme.The compounds underwent testing within the range of 1000 to 50 µM.For more data on the additional compound *5, please refer to [43].(c) The impact of LfcinB and its conjugate 4 on intracellular ROS generation in HL60 and HEK293 measured using CM-H2DCFDA.(d) Dot plots illustrating the mitochondrial potential of HL60-treatedcompound 3, assessed through DIOC6(3) staining.A positive control with 50 µM CCCP was applied.LB, left bottom; RB, right bottom; LT, left top; RT, right top.Flow data were analyzed by Flowing Software 2.5.1 (Turku Bioscience, Turku, Finland).Values represented from three independent experiments.2.3.2.DNA Gyrase and Topoisomerase IV Inhibition

Figure 2 .
Figure 2. Effectiveness of LfcinB and its bioconjugates in biological systems.(a) The bactericidal activity of LfcinB and its bioconjugate 3. Two-parameter dot plots showcase the shift in the asymmetric localization of phosphatidylserine in the external membrane induced by the compound in S. aureus (Annexin V-positive events derived from the right top and bottom squares of the discriminator).The outcomes of the flow cytometry were analyzed with the free online software Floreada.io(https://floreada.io/(accessed on 30 November 2023; the last update was carried out in June 2023)).Representative data are based on three independent repetitions.(b) The compound hinders the supercoiling activity of gyrase.Controls include K BZ , representing the sample without the compound, and K BE , representing the sample without the enzyme.The compounds underwent testing within the Supplementary Figure S1.Compound *5 was synthesized according to the procedure described in Ptaszy ńska et al. (2018).All drugs were dissolved in DMSO at concentrations ranging from 2 to 10 mM and stored at −20 • C. The 7-AAD was dissolved in MeOH:H 2 O (4:6) and stored at 4 • C.